产品
编 号：F179105
分子式：C26H42N4O5
分子量：490.64
分子式：C26H42N4O5
分子量：490.64
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 151823-14-2
产品详情
生物活性：
Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.
体内研究：
On Day 14, the Sapacitabine (5?mg/kg)+vorinostat (33?mg/kg) group has a mean tumour volume of 245?mm3 and a tumour growth inhibition (TGI) of 92%, whereas the Sapacitabine (15?mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 107?mm3 and a TGI of 112%.
体外研究：
Concentrations of Sapacitabine required to achieve an IC50 range from 3±0.6?μM for the colon cancer cell line HCT116 to 67±14?μM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in G2/M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, (IC50 20±6 μM).In the docetaxel/Sapacitabine combinations, synergistic effects (CISapacitabine 相关抗体:
Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.
体内研究：
On Day 14, the Sapacitabine (5?mg/kg)+vorinostat (33?mg/kg) group has a mean tumour volume of 245?mm3 and a tumour growth inhibition (TGI) of 92%, whereas the Sapacitabine (15?mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 107?mm3 and a TGI of 112%.
体外研究：
Concentrations of Sapacitabine required to achieve an IC50 range from 3±0.6?μM for the colon cancer cell line HCT116 to 67±14?μM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in G2/M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, (IC50 20±6 μM).In the docetaxel/Sapacitabine combinations, synergistic effects (CISapacitabine 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备